YPC12 cells treated either with empty nanocapsules or nicotine containingFigure 7. Viability
YPC12 cells treated either with empty nanocapsules or nicotine containingFigure 7. Viability PC12 cells a single day immediately after a variety of treatments with with nanocapsules. = empty Figure 7. Viability ofof PC12 cells 1 day following numerous treatmentsnanocapsules. EN 100 EN one hundred = emptyFigure 7. Viability of two); EN cells=one nanocapsules (group treatments= nicotine containing EN 1 nanocapsules (group EN 500 = empty day after several three); NNC one hundred with = nicotine containing nanocapsules (group 2);PC12 500 empty nanocapsules (group 3); NNC 100 nanocapsules. nanocapsules (group 2); EN 500 = empty containing nanocapsules 500 (group M nicotine nanocapsules one hundred (group four); NNC 500 = nicotinenanocapsules (group three); NNC one hundred =(group 5); nanocapsules 100 M (group four); NNC 500 = nicotine containing nanocapsules 500 5); NIC NIC 100 of bulk bulk nicotine (group six); NIC 500 = 500 M nicotine (group (group 7); (: 100 = 100 = 100M of nicotine (group 6); NIC 500 = 500 of bulkof bulk nicotine7); (: p 0.05500 0.05 nanocapsules one hundred M (group four); NNC 500 = nicotine containing nanocapsules p M samples vs. manage), samples = 100M n n = three. NIC one hundred vs. control),of = three. nicotine (group 6); NIC 500 = 500 M of bulk nicotine (group 7) bulk samples vs. handle), day 3. was also assessed by LIVE/DEAD assay (Figure 9), which Cell viability at n = 7 7 was also assessed by LIVE/DEAD assay (Figure 9), which corCell viability at day corroborated the MTT final results. roborated the MTT results.3.3. Cytokine UCB-5307 Purity Expression Evaluation The expression of cytokines TNF-, IL-6 and IL-10 had been evaluated by ELISA. IL-10 was not detected in our samples. At day one, IL-6 was substantially elevated within the groups with larger empty nanocapsule concentration (EN500) and greater nicotine containingCell viability at day 7 was also assessed by LIVE/DEAD assay (Figure 9), w roborated the MTT benefits.Bioengineering 2021, 8,10 ofBioengineering 2021, eight, x FOR PEER Overview nanocapsule concentration (NNC500) (Figure ten). This improve is even more evident 3 days immediately after therapy (Figure 11). Each groups of cells treated with bulk nicotine showed no distinction in expression compared to the handle groups.Bioengineering 2021, 8, x FOR PEER Evaluation 10 ofFigure 8. Viability of of PC12 cells at seven culture. culture. EN 100 = empty (group 2); EN 500 Figure 8. ViabilityPC12 cells at seven days in days inEN 100 = empty SC-19220 Epigenetic Reader Domain nanocapsulesnanocapsules (grou 500 = empty nanocapsules (group three); NNC 100 = nicotine containing nanocapsules 100 (group four); = empty nanocapsules (group 3); NNC NNC 100 = containing nanocapsules (group 4); M = NNC 500nanocapsules (group three); 100 = nicotine nicotine containing100100 Mbulk nicotine empty = nicotine containing nanocapsules 500 (group five); NIC one hundred = nanocapsules 100NNC (gro of 500 = nicotine containing nanocapsules 500 M (group 5); NIC 100 = one hundred M of bulk nicotine (group 6); (group 6); NIC containing nanocapsules (group 7); (: p five); NIC one hundred = of bulk nicotine 500 = nicotine 500 = 500 nicotine (group 7); (:5000.05 samples0.05 manage); n = 3. 100 M of bulk nicotin M (group samples vs. control); n = three. NIC 500 = 500 M of bulk p vs. NIC 500 = 500 M of bulk nicotine (group 7); (: p 0.05 samples vs. handle); n = 3.Figure eight. Viability of PC12 cells at seven days in culture. EN 100 = empty nanocapsules (group two); ENFigure 9. Cont.Bioengineering 2021, 8,11 ofBioengineering 2021, 8, x FOR PEER REVIEW11 ofFigure 9. LIVE/DEAD pictures of PC12 cells 7 days in culture right after therapy with nanocapsules. (A) control gro.